HAEMONETICS CORP's ticker is HAE and the CUSIP is 405024100. A total of 258 filers reported holding HAEMONETICS CORP in Q4 2021. The put-call ratio across all filers is 0.26 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $1,470,635 | +22.5% | 16,417 | +16.4% | 0.13% | +27.7% |
Q2 2023 | $1,200,985 | +4.5% | 14,106 | +1.6% | 0.10% | +2.0% |
Q1 2023 | $1,149,398 | +18.4% | 13,890 | +12.5% | 0.10% | +28.6% |
Q4 2022 | $970,777 | +26.2% | 12,343 | +18.8% | 0.08% | -4.9% |
Q3 2022 | $769,000 | +13.8% | 10,389 | +0.1% | 0.08% | +19.1% |
Q2 2022 | $676,000 | +30.3% | 10,376 | +26.4% | 0.07% | +44.7% |
Q1 2022 | $519,000 | +68.0% | 8,211 | +40.7% | 0.05% | +74.1% |
Q4 2021 | $309,000 | -8.8% | 5,834 | +21.5% | 0.03% | -22.9% |
Q3 2021 | $339,000 | +24.2% | 4,803 | +17.2% | 0.04% | +29.6% |
Q2 2021 | $273,000 | +1.9% | 4,098 | +69.5% | 0.03% | -10.0% |
Q1 2021 | $268,000 | -6.9% | 2,417 | -0.5% | 0.03% | -16.7% |
Q4 2020 | $288,000 | +42.6% | 2,428 | +4.8% | 0.04% | +24.1% |
Q3 2020 | $202,000 | +119.6% | 2,317 | +126.5% | 0.03% | +123.1% |
Q2 2020 | $92,000 | 0.0% | 1,023 | +11.3% | 0.01% | -18.8% |
Q1 2020 | $92,000 | – | 919 | – | 0.02% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Millrace Asset Group, Inc. | 19,264 | $1,726 | 2.13% |
Parkman Healthcare Partners LLC | 88,962 | $7,969,216 | 1.46% |
HEARTLAND ADVISORS INC | 256,414 | $24,435,274 | 1.37% |
Riverwater Partners LLC | 15,553 | $1,393,238 | 1.27% |
KINGDON CAPITAL MANAGEMENT, L.L.C. | 111,100 | $9,952,338 | 1.15% |
Lisanti Capital Growth, LLC | 78,425 | $7,025,312 | 1.11% |
Aristotle Capital Boston, LLC | 311,666 | $27,919,054 | 0.90% |
ROYCE & ASSOCIATES LP | 947,550 | $84,881,529 | 0.86% |
CHASE INVESTMENT COUNSEL CORP | 18,770 | $1,681 | 0.84% |
Virtus Investment Advisers, Inc. | 13,662 | $1,223,842 | 0.83% |